^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IMP7068
i
Other names: IMP7068, IMP-7068, IMP 7068
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
IMPACT Therap
Drug class:
WEE1 inhibitor
Related drugs:
over1year
Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors (ESMO 2023)
80mg was defined as a potential PR2D in 3/4 schedule, and a second potential RP2D is being explored in 5/2 schedule. RP2D for IMP7068 will be determined soon.
Clinical • Metastases
|
CDK1 (Cyclin-dependent kinase 1)
|
IMP7068
2years
WEE1: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=350, Recruiting, Impact Therapeutics, Inc. | N=150 --> 350
Enrollment change • Metastases
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
|
MSI-H/dMMR • NTRK fusion
|
IMP7068
over3years
WEE1: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=150, Recruiting, Impact Therapeutics, Inc. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
|
MSI-H/dMMR • NTRK fusion
|
IMP7068
over3years
WEE1: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=150, Not yet recruiting, Impact Therapeutics, Inc.
Clinical • New P1 trial
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
|
MSI-H/dMMR • NTRK fusion
|
IMP7068
Share via
